LDS/Medical Tests/Estrogen/Progesterone Receptor, IHC, Semi-Quantitative

Estrogen/Progesterone Receptor, IHC, Semi-Quantitative

Breast cancer is often hormone-driven, specifically by estrogen, and less often by progesterone. Positive cancer cells have estrogen and progesterone receptors in the nucleus. Patients whose cancers are ER and/or PR positive often benefit from anti-estrogen therapy with agents such as Tamoxifen. About a third of patients with ER positive metastatic breast cancer will show benefit from anti-estrogen therapy. ER negative patients almost never benefit from anti-estrogen therapy. Thus, ER expression is one of the most important factors in determining response to endocrine therapy. Overall, about 55% of premenopausal and 75% of postmenopausal patients are ER positive. ER status can change during the course of a patient’s disease. Most commonly there is loss of ER and/or PR positivity. Since a progesterone receptor is estrogen-inducible it is usually present mostly in estrogen positive cancers. Estrogen/progesterone receptor assays are performed on malignant breast tissue to assess prognosis and to determine which patients will most likely benefit from chemotherapy or hormonal manipulation. There are several methodologies, the most recent being immunohistochemistry staining of slide-mounted sections of paraffin embedded tissue. Prior methodologies of competitive radioimmunoassay and enzyme-linked immunoassay of cytosolic extracts were subject to false positive and false negative results as well as requiring fresh or frozen tissue in larger amounts, thermolability, contamination and interference from endogenous hormones, or exogenous hormone therapy. Estrogen/progesterone receptor assays are also occasionally performed on tumors of the female genital tract.

  • Differential diagnosis and therapy evaluation of breast cancer
  • Disease management and therapy monitoring
  • Predicting patient response to hormonal therapy
  • Prognosis and patient response to adjuvant endocrine therapy
Tumor ER and PR Receptor status is termed as being Positive or Negative. Individuals with receptor-positive tumors generally have a better prognosis, as indicated by a longer interval to disease recurrence and a longer overall survival, than patients with receptor-negative tumors.

Determination of receptor status positivity is methodology dependent. In immunohistochemistry the percentage of positively stained tumor nuclei are determined and their relative intensity evaluated by counting individual cells microscopically, with cutoffs established.  The cutoff for positive ER and PR by IHC is usually >/= 1% of tumor cells staining positive.
 

 

 

Immunohistochemical staining of slide mounted sections from paraffin embedded tissue.

Test dependent. Currently immunohistochemistry is used so that paraffin embedded tissue is used. This can be stored for years.

Gene expression profile testing, Tumor proliferation rate, S-phase fraction, DNA ploidy and Her-2/neu status by immunohistochemistry or Fluorescence In Situ Hybridization.

3-5 days. 

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login